MX2018009948A - Formulaciones de oritavancina. - Google Patents
Formulaciones de oritavancina.Info
- Publication number
- MX2018009948A MX2018009948A MX2018009948A MX2018009948A MX2018009948A MX 2018009948 A MX2018009948 A MX 2018009948A MX 2018009948 A MX2018009948 A MX 2018009948A MX 2018009948 A MX2018009948 A MX 2018009948A MX 2018009948 A MX2018009948 A MX 2018009948A
- Authority
- MX
- Mexico
- Prior art keywords
- oritavancin
- formulations
- cyclodextrin
- salt
- modified
- Prior art date
Links
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 title abstract 2
- 229960001607 oritavancin Drugs 0.000 title abstract 2
- 108010006945 oritavancin Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen en la presente composiciones antibacterianas, composiciones farmacéuticas, y el uso y preparación de las mismas. Algunas modalidades se refieren a composiciones que incluyen oritavancina y su uso como agentes terapéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296989P | 2016-02-18 | 2016-02-18 | |
| PCT/US2017/018340 WO2017143169A1 (en) | 2016-02-18 | 2017-02-17 | Oritavancin formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009948A true MX2018009948A (es) | 2018-12-06 |
Family
ID=59625418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009948A MX2018009948A (es) | 2016-02-18 | 2017-02-17 | Formulaciones de oritavancina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170239323A1 (es) |
| EP (1) | EP3416672B1 (es) |
| JP (1) | JP2019512538A (es) |
| KR (1) | KR20180111948A (es) |
| CN (1) | CN108712909A (es) |
| AU (1) | AU2017221435A1 (es) |
| BR (1) | BR112018016715A2 (es) |
| CA (1) | CA3014294A1 (es) |
| CL (1) | CL2018002368A1 (es) |
| CO (1) | CO2018008626A2 (es) |
| ES (1) | ES2991243T3 (es) |
| HU (1) | HUE069322T2 (es) |
| IL (1) | IL261013A (es) |
| MX (1) | MX2018009948A (es) |
| PH (1) | PH12018501758A1 (es) |
| RU (1) | RU2018129076A (es) |
| WO (1) | WO2017143169A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190005940A (ko) * | 2016-05-09 | 2019-01-16 | 셀리아 파마슈티칼즈 에이피에스 | 안정화된 글리코펩티드 항생제 제형 |
| EP3923896A1 (en) * | 2019-02-12 | 2021-12-22 | Amgen Inc. | Systems and approaches for drug delivery device reconstitution |
| CN117618338A (zh) * | 2022-08-16 | 2024-03-01 | 海南普利制药股份有限公司 | 一种稳定的奥利万星药物水溶液及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6026482B2 (ja) | 1980-07-31 | 1985-06-24 | 日本食品化工株式会社 | サイクロデキストリンの製造方法 |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4808232A (en) | 1986-12-08 | 1989-02-28 | American Maize-Products Company | Separation and purification of cyclodextrins |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| CA2726789A1 (en) * | 2000-02-05 | 2001-11-08 | Theravance, Inc. | Cyclodextrin containing glycopeptide antibiotic compositions |
| WO2001083520A2 (en) * | 2000-05-02 | 2001-11-08 | Theravance,Inc | Polyacid glycopeptide derivatives |
| WO2004110473A1 (en) * | 2003-05-27 | 2004-12-23 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| EP1654036B1 (en) * | 2003-07-22 | 2007-12-26 | Theravance, Inc. | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| CA2699550C (en) | 2007-09-12 | 2020-08-18 | Targanta Therapeutics Corp. | Method of inhibiting clostridium difficile by administration of oritavancin |
| HUE027373T2 (hu) | 2008-08-30 | 2016-09-28 | The Medicines Co | Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával |
| AU2010245097B2 (en) * | 2009-04-28 | 2015-08-13 | Melinta Therapeutics, Inc. | Methods of treating bacterial infections using oritavancin |
| US8901072B2 (en) * | 2009-08-12 | 2014-12-02 | The Medicines Company | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
| EP2737077B1 (en) | 2011-07-26 | 2016-11-16 | The Medicines Company | Disk diffusion assay for oritavancin |
| MX390762B (es) | 2012-02-28 | 2025-03-19 | Cydex Pharmaceuticals Inc | Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas |
| WO2014176068A2 (en) * | 2013-04-22 | 2014-10-30 | The Medicines Company | Treatment and prevention of bacterial skin infections using oritavancin |
| WO2015031313A2 (en) * | 2013-08-26 | 2015-03-05 | The Medicines Company | Methods for treating bacteremia and osteomyelitis using oritavancin |
-
2017
- 2017-02-17 KR KR1020187025824A patent/KR20180111948A/ko not_active Withdrawn
- 2017-02-17 AU AU2017221435A patent/AU2017221435A1/en not_active Abandoned
- 2017-02-17 EP EP17753910.3A patent/EP3416672B1/en active Active
- 2017-02-17 ES ES17753910T patent/ES2991243T3/es active Active
- 2017-02-17 HU HUE17753910A patent/HUE069322T2/hu unknown
- 2017-02-17 US US15/436,391 patent/US20170239323A1/en not_active Abandoned
- 2017-02-17 WO PCT/US2017/018340 patent/WO2017143169A1/en not_active Ceased
- 2017-02-17 JP JP2018563382A patent/JP2019512538A/ja not_active Withdrawn
- 2017-02-17 RU RU2018129076A patent/RU2018129076A/ru not_active Application Discontinuation
- 2017-02-17 CN CN201780012128.1A patent/CN108712909A/zh not_active Withdrawn
- 2017-02-17 MX MX2018009948A patent/MX2018009948A/es unknown
- 2017-02-17 BR BR112018016715-0A patent/BR112018016715A2/pt active IP Right Grant
- 2017-02-17 CA CA3014294A patent/CA3014294A1/en not_active Abandoned
-
2018
- 2018-08-06 IL IL261013A patent/IL261013A/en unknown
- 2018-08-16 CO CONC2018/0008626A patent/CO2018008626A2/es unknown
- 2018-08-17 PH PH12018501758A patent/PH12018501758A1/en unknown
- 2018-08-17 CL CL2018002368A patent/CL2018002368A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019512538A (ja) | 2019-05-16 |
| KR20180111948A (ko) | 2018-10-11 |
| CA3014294A1 (en) | 2017-08-24 |
| EP3416672A1 (en) | 2018-12-26 |
| WO2017143169A1 (en) | 2017-08-24 |
| EP3416672A4 (en) | 2019-09-18 |
| RU2018129076A (ru) | 2020-03-18 |
| EP3416672C0 (en) | 2024-10-23 |
| US20170239323A1 (en) | 2017-08-24 |
| AU2017221435A1 (en) | 2018-09-06 |
| CL2018002368A1 (es) | 2018-11-16 |
| RU2018129076A3 (es) | 2020-06-25 |
| EP3416672B1 (en) | 2024-10-23 |
| HUE069322T2 (hu) | 2025-03-28 |
| ES2991243T3 (es) | 2024-12-03 |
| IL261013A (en) | 2018-10-31 |
| BR112018016715A2 (pt) | 2019-02-19 |
| PH12018501758A1 (en) | 2019-06-17 |
| CN108712909A (zh) | 2018-10-26 |
| CO2018008626A2 (es) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010168A (es) | Moduladores de calpainas y usos terapeuticos de los mismos. | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| ZA201906451B (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MX2017016802A (es) | Formulaciones farmaceuticas. | |
| IL272638A (en) | History of quinoxaline, their preparation and pharmaceutical preparations containing them | |
| IL276952A (en) | History of 4,2-diaminoquinazolines and their medicinal uses | |
| EP3381925A4 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
| IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
| EP4331622A3 (en) | Integrin binding peptides and uses thereof | |
| WO2016130581A3 (en) | Combination cancer therapy | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| IL272284A (en) | History of thiazolopyridines, their preparation and pharmaceutical preparations containing them | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| EP3497080A4 (en) | PHARMACEUTICAL FORMULATIONS AND THEIR USE | |
| PH12021550090A1 (en) | Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof | |
| EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| EP3604291A4 (en) | COMPOUND OR SALT THEREOF, ANTIVIRAL AGENT AND PHARMACEUTICAL COMPOSITION | |
| EP3718543A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| HK40040915A (en) | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications | |
| HK40060495A (en) | Aqueous pharmaceutical formulations |